These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32057199)

  • 21. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
    Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting disability worsening in relapsing and progressive multiple sclerosis.
    Simmons SB; Schippling S; Giovannoni G; Ontaneda D
    Curr Opin Neurol; 2021 Jun; 34(3):312-321. PubMed ID: 33709974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM/TSP) and multiple sclerosis (MS).
    Azodi S; Nair G; Enose-Akahata Y; Charlip E; Vellucci A; Cortese I; Dwyer J; Billioux BJ; Thomas C; Ohayon J; Reich DS; Jacobson S
    Ann Neurol; 2017 Nov; 82(5):719-728. PubMed ID: 29024167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Sechi E; Messina S; Keegan BM; Buciuc M; Pittock SJ; Kantarci OH; Weinshenker BG; Flanagan EP
    Mult Scler; 2021 Apr; 27(5):667-673. PubMed ID: 32552535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive Multiple Sclerosis.
    Ontaneda D
    Continuum (Minneap Minn); 2019 Jun; 25(3):736-752. PubMed ID: 31162314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of new and chronic cortical lesions to disability accrual in multiple sclerosis.
    Beck ES; Mullins WA; Dos Santos Silva J; Filippini S; Parvathaneni P; Maranzano J; Morrison M; Suto DJ; Donnay C; Dieckhaus H; Luciano NJ; Sharma K; Gaitán MI; Liu J; de Zwart JA; van Gelderen P; Cortese I; Narayanan S; Duyn JH; Nair G; Sati P; Reich DS
    Brain Commun; 2024; 6(3):fcae158. PubMed ID: 38818331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
    van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
    Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
    Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.
    Tanaka K; Kujuro Y; Suzuki S; Tanahashi N; Hamada J; Nogawa S; Suzuki N
    Intern Med; 2005 Jun; 44(6):560-6. PubMed ID: 16020880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
    PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silent progression in disease activity-free relapsing multiple sclerosis.
    ; Cree BAC; Hollenbach JA; Bove R; Kirkish G; Sacco S; Caverzasi E; Bischof A; Gundel T; Zhu AH; Papinutto N; Stern WA; Bevan C; Romeo A; Goodin DS; Gelfand JM; Graves J; Green AJ; Wilson MR; Zamvil SS; Zhao C; Gomez R; Ragan NR; Rush GQ; Barba P; Santaniello A; Baranzini SE; Oksenberg JR; Henry RG; Hauser SL
    Ann Neurol; 2019 May; 85(5):653-666. PubMed ID: 30851128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.